← Eichor
Study identifier: NCT01019148 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Condition: Epidermolysis Bullosa Dystrophica  ·  Sponsor: Stanford University

PhaseN/A
Planned participants70
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.

This description comes directly from the study's public registry record.

Talk to the study team

Irene Bailey-Healy  ·  (650) 721-7149  ·  baileyhi@stanford.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Stanford University School of MedicineStanford, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01019148